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The serine hydrolase a/b hydrolase domain 6
(ABHD6) has recently been implicated as a key
lipase for the endocannabinoid 2-arachidonylgly-
cerol (2-AG) in the brain. However, the biochemical
and physiological function for ABHD6 outside of the
central nervous system has not been established.
To address this, we utilized targeted antisense oli-
gonucleotides (ASOs) to selectively knock down
ABHD6 in peripheral tissues in order to identify in vivo
substrates and understand ABHD6’s role in energy
metabolism. Here, we show that selective knock-
down of ABHD6 in metabolic tissues protects mice
from high-fat-diet-induced obesity, hepatic steato-
sis, and systemic insulin resistance. Using combined
in vivo lipidomic identification and in vitro enzy-
mology approaches, we show that ABHD6 can hy-
drolyze several lipid substrates, positioning ABHD6
at the interface of glycerophospholipid metabolism
and lipid signal transduction. Collectively, these
data suggest that ABHD6 inhibitors may serve as
therapeutics for obesity, nonalcoholic fatty liver dis-
ease, and type II diabetes.
INTRODUCTION
A major challenge for drug discovery in the postgenomic era is
the functional characterization of unannotated genes identified
by sequencing efforts. Although many unannotated gene prod-
ucts belong to structurally related gene or protein families,
which may provide important functional clues, membership508 Cell Reports 5, 508–520, October 31, 2013 ª2013 The Authorsto such families does not always accurately predict the true
biochemical and physiological role of proteins. Genes encod-
ing the a/b hydrolase fold domain (ABHD) protein family are
present in all reported genomes (Nardini and Dijkstra, 1999;
Hotelier et al., 2004), and conserved structural motifs shared
by these proteins predict common roles in lipid metabolism
and signal transduction (Lefe`vre et al., 2001; Fiskerstrand
et al., 2010; Long et al., 2011; Simon and Cravatt, 2006;
Montero-Moran et al., 2010; Blankman et al., 2007; Lord
et al., 2012; Brown et al., 2010). Furthermore, mutations in
several members of the ABHD protein family have been impli-
cated in inherited inborn errors of lipid metabolism (Lefe`vre
et al., 2001; Fiskerstrand et al., 2010). Most recently, studies
in cell and animal models have revealed important roles for
ABHD proteins in glycerophospholipid metabolism, lipid signal
transduction, and metabolic disease (Long et al., 2011; Simon
and Cravatt 2006; Montero-Moran et al., 2010; Blankman
et al., 2007; Lord et al., 2012; Brown et al., 2010). However,
the physiological substrates and products for these lipid
metabolizing enzymes and their broader role in metabolic
pathways remain largely uncharacterized. Given this, functional
annotation of ABHD enzymes holds clear promise for drug dis-
covery targeting diseases of altered lipid metabolism and lipid
signaling.
ABHD5, also known as CGI-58, has been studied quite
extensively due to its key role in triacylglycerol (TAG) meta-
bolism, lipid signaling, and genetic association with the human
disease Chanarin-Dorfman Syndrome (CDS) (Lefe`vre et al.,
2001; Montero-Moran et al., 2010; Lord et al., 2012; Brown
et al., 2010; Lass et al., 2006; Schweiger et al., 2009). Given
ABHD5’s clear role in nutrient metabolism and lipid signal
transduction, we aimed to test whether the closely related
enzyme ABHD6 might play a similar role in lipid signaling and
metabolic disease. ABHD6 has recently been described as an
Figure 1. ABHD6 Is Ubiquitously Expressed
and Is Regulated by High-Fat Diet
(A) Alignment of human (Hu), macaque (Ma), rat
(Ra), and mouse (Mu) ABHD6 orthologs showing
conserved (gray) and divergent residues (white); C,
consensus sequence. The underlined letters
represent the consensus GXSXG ‘‘nucleophile
elbow’’ containing the predicted serine nucleophile
S148 (black box).
(B)mRNA expression analysis of ABHD6 in C57BL/
6 mouse tissues following 10 weeks of chow or
high-fat diet (HF) feeding. Data represent the
mean ± SEM (n = 4); *p < 0.05 (versus chow-fed
group within each tissue). AU, arbitrary units; Liv,
liver; He, heart; Lu, lung; BAT, brown adipose tis-
sue; Kid, kidney; Spl, spleen; small intestine seg-
ments proximal to distal are labeled SI-1, SI-2, and
SI-3; Te, testes; Br, brain; Mu, skeletal muscle.enzymatic regulator of endocannabinoid (ECB) signaling in the
brain (Blankman et al., 2007; Marrs et al., 2010, 2011). How-
ever, ABHD6 is ubiquitously expressed, and the biochemical
and physiological functions of ABHD6 outside of the central
nervous system have not been studied. Furthermore, unbiased
identification of ABHD6 substrates in vivo has not been re-
ported. To address this, we selectively knocked down ABHD6
in peripheral tissues, allowing us to identify substrates in vivo
and to uncover a previously underappreciated role for ABHD6
in promoting the metabolic syndrome. These studies demon-
strate that ABHD6 plays a nonredundant enzymatic role in pro-
moting the metabolic disorders induced by high-fat feeding andCell Reports 5, 508–520suggest that ABHD6 inhibition may be
effective in preventing obesity, nonal-
coholic fatty liver disease, and type II
diabetes.
RESULTS
ABHD6 Is Ubiquitously Expressed
and Upregulated by High-Fat-Diet
Feeding
Mouse ABHD6 is a 336 amino acid protein
that shares high sequence identity with its
human (94%), macaque (94%), and rat
(97%) orthologs (Figure 1A). A highly
conserved active site serine nucleophile
is found at residue 148 (Figure 1A), which
is predicted to be necessary for enzyme
catalysis. ABHD6 mRNA is ubiqui-
tously expressed (Figure 1B), with highest
expression in small intestine, liver, and
brown adipose tissue in mice fed stan-
dard rodent chow. Additionally, high-fat-
diet feeding increases ABHD6 mRNA
expression in the small intestine and
the liver (Figure 1B). This transcriptional
regulation of ABHD6 in metabolic tis-
sue prompted us to examine whetherABHD6 may be an important mediator of high-fat-diet-induced
metabolic disease.
ABHD6 Knockdown Protects against High-Fat-Diet-
Induced Obesity
To examine the role of ABHD6 in lipid metabolism in peripheral
tissues without altering expression in the brain, we utilized anti-
sense oligonucleotide (ASO) targeting (Crooke, 1997). Initially,
we tested four separate ASOs targeting murine ABHD6 and
found that all reduced hepatic ABHD6 mRNA by >80% after
4 weeks of administration (Figures S1A and S2A). Following
12 weeks of ASO knockdown with two of our ABHD6 ASOs, October 31, 2013 ª2013 The Authors 509
(legend on next page)
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(ASOa and ASOb), we observed tissue selective knockdown of
ABHD6 protein with the following rank order: liver (>90%) >white
adipose tissue (>90%) > kidney (50%) (Figures 2A and S1B). In
contrast, ABHD6 protein expression in the brain, spleen, and
brown adipose tissue was relatively unaffected by ASO treat-
ment (Figure S1B). Given that ABHD6 has been described as a
key enzymatic regulator of endocannabinoid signaling in the
brain (Blankman et al., 2007; Marrs et al., 2010, 2011), we care-
fully examined whether ASO treatment reduced ABHD6 in brain
regions relevant to metabolic disease. Importantly, ABHD6 was
not altered in the hippocampus (Figure S1D), whereas livers from
the samemice showedmarked reductions in ABHD6 expression
in the liver (Figure S1C). Furthermore, the mRNA expression of
ABHD6 in the hypothalamus was likewise not altered by ASO
treatment (Figure S1E).
ABHD6 ASO treatment did not alter body weight (Figure 2B),
adiposity (Figure 2E), or food intake (Figure 2H) in mice fed a
standard rodent chow diet. However, when challenged with a
high-fat diet, ABHD6 ASO-treated mice were protected from
diet-induced body weight gain (Figures 2B and 2C), which was
in large part due to a reduction in adipose tissue (Figure 2D).
MRI showed that ABHD6 ASO treatment significantly reduced
body fat mass (Figure 2E) without altering lean body mass (Fig-
ure 2F). Furthermore, ABHD6 ASO treatment did not result in
general growth retardation, given that snout to anus lengths
were unaffected (Figure 2G). The protection from high-fat-diet-
induced obesity in ABHD6 ASO-treated mice could not be ex-
plained by reductions in food intake (Figure 2H) or by reductions
in intestinal fat absorption (Figure 2I). In fact, the absorption of
several long-chain fatty acids was actually slightly increased in
ABHD6 ASO-treated mice (Table S1). Gene expression analysis
in epididymal white adipose tissue revealed that ABHD6 knock-
down caused increased expression of lipolytic genes such as
HSL and MAGL (Figure 2J), with very minor changes in lipogenic
gene expression such as SREBP1c and SCD1 in white adipose
tissue (Figure 2J). The ability of ABHD6 ASO treatment to protect
against high-fat-diet-induced obesity could be explained in part
by increases in physical activity during the dark cycle (Figure 2K)Figure 2. ASO-Mediated Knockdown of ABHD6 Protects against High
(A) ABHD6 protein levels in the liver, epididymal white adipose tissue (WAT), an
separate ABHD6 ASOs for 12 weeks.
(B) Body weight in chow-fed or high-fat-diet (HFD)-fed mice; data represent th
time point).
(C) Gross appearance of HFD-fed mice.
(D) Gross appearance of epididymal fat pads in HFD-fed mice, and total epididym
± SEM (n = 6–9); *p < 0.05 (versus control ASO within each diet).
(E) Body fat percentage as measured by MRI (n = 4).
(F) Lean body mass as measured by MRI (n = 4).
(G) Snout to anus length (n = 10).
(H) Cumulative food intake in ASO-treated mice (n = 10).
(I) Total intestinal fat absorption in mice treated with ASOs and fed a HFD for 9 w
(J) qPCR analyses of epididymal adipose tissue (WAT) gene expression in HFD-fe
group). ATGL, adipose triglyceride lipase; HSL, hormone-sensitive lipase, MAGL
1c; FAS, fatty acid synthase; ACC1, acetyl-CoA carboxylase 1; SCD1, stearoyl-C
(K) Diurnal and nocturnal quantification of physical activity (total beam break cou
(L) Diurnal and nocturnal quantification of oxygen consumption (VO2).
(M) Diurnal and nocturnal quantification of respiratory exchange ratio (RER; VCO2
for at least 48 hr prior to measurement. Data represent the mean ± SEM (n = 4);
See also Figure S1 and Table S1.
Cand increases in energy expenditure during both the diurnal and
nocturnal phases (Figure 2L). There were no detectable alter-
ations in the respiratory exchange ratio (RER) in control and
ABHD6 ASO-treated mice fed a high-fat diet (Figure 2M).
ABHD6 Knockdown Protects against Metabolic
Disorders Induced by High-Fat Feeding
ABHD6 knockdown significantly reduced high-fat-diet-induced
accumulation of total hepatic triacylglycerol (TAG) (Figure 3A)
without altering total hepatic levels of diacylglycerols (DAG) or
monoacylglycerols (MAG) in either dietary setting (Figure 3B).
This reduction in neutral lipids was observed in almost all molec-
ular species of TAG, with the exception of 56:6 TAG (Figure S3A).
ABHD6 ASO treatment significantly blunted high-fat-diet-driven
increases in some hepatic DAG species (32:2, 32:1, 34:3, 34:2,
34:1, and 38:6), but not in others (36:2) (Figure S3B). In parallel,
ABHD6 knockdown protected mice from high-fat-diet-induced
hyperglycemia (Figure 3C), hyperinsulinemia (Figure 3D) and
improved both glucose and insulin tolerance (Figures 3H and
3I). Interestingly, reducing ABHD6 did not alter plasma TAG
levels on either diet (Figure 3E), yet knockdown increased
plasma nonesterified fatty acid (NEFA) levels specifically in
high-fat-diet-fed mice (Figure 3G). Additionally, ABHD6 ASO
treatment did not alter very-low-density lipoprotein (VLDL)
triacylglycerol secretion rates (Figure 3J). However, ABHD6
knockdown protected against high-fat-diet-induced hypercho-
lesterolemia (Figure 3F), which was reflected as a significant
decrease in LDL and a modest increase in high-density lipopro-
tein (HDL) levels (data not shown). Importantly, hepatic short
chain TAG species were significantly decreased by ABHD6
ASO treatment (50:4, 52:5, 52:4, and 54:7) in chow-fed mice,
where systemic insulin sensitivity and plasma triacylglycerol
levels were similar to control mice (Figure S4).
ABHD6 Is a Critical Regulator of De Novo Fatty Acid
Synthesis
When comparing global hepatic gene expression between high-
fat-diet-fed control versus ABHD6 ASO-treated mice, we found-Fat-Diet-Induced Obesity
d brain of mice treated with either saline, a control nontargeting ASO, or two
e mean ± SEM (n = 6–9); *p < 0.05 (versus control ASO group within each
al fat pad weight in both chow-fed and HFD-fed mice; data represent the mean
eeks (n = 14–15).
d mice; data represent the mean ± SEM (n = 4); *p < 0.05 (versus control ASO
, monoacylglycerol lipase; SREBP1c, sterol response element-binding protein
oA desaturase 1; AU, arbitrary unit.
nts).
/VO2). For metabolic cage studies, mice were weight matched and acclimated
*p < 0.05 (versus control ASO).
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Figure 3. ASO-Mediated Knockdown of ABHD6 Protects against Metabolic Disorders Induced by High-Fat Feeding
Mice were fed a chow or high-fat diet (HFD) and treated with a control ASO or an ASO targeting ABHD6 for 12 weeks.
(A) Gross appearance of livers and microscopic examination (hematoxylin and eosin staining at 403 magnification) in HFD-fed mice.
(B) Total hepatic levels of triacylglycerols (TAG), diacylglycerols (DAG), and monoacylglycerols (MAG) in mice fed diets for 12 weeks.
(C) Plasma glucose levels in mice treated with ASOs and diets for 10–11 weeks.
(D) Plasma insulin levels in mice treated with ASOs and diets for 12 weeks.
(E) Plasma TAG levels in mice treated with ASOs and diets for 12 weeks.
(F) Plasma cholesterol levels in mice treated with ASOs and diets for 12 weeks.
(G) Plasma nonesterified fatty acids (NEFAs) in mice treated with ASOs and diets for 12 weeks.
(H) Glucose tolerance tests in mice treated with ASOs and diets for 10–11 weeks.
(I) Insulin tolerance tests in mice treated with ASOs and diets for 10–11 weeks.
(J) Hepatic VLDL-TAG secretion rates in mice treated with ASOs and high-fat diet for 11 weeks.
All data represent the mean ± SEM (n = 4–6); *p < 0.05 (versus control ASO within each diet). See also Figures S2, S3, and S4.a surprisingly small number of genes that were differentially
expressed by greater than 2-fold (167 upregulated genes and
138 downregulated genes; p < 0.005) (Figure 4A). Themost high-
ly enriched gene ontology (log[p value] = 10) regulated by
ABHD6 knockdown was fatty acid metabolism (Figure 4A).
ABHD6 ASO treatment resulted in a 50% reduction in hepatic
ABHD5 expression, which is unlikely to be from direct ASO-
mediated silencing due to lack of sequence homology between
the two mRNAs. Knockdown of ABHD6 also increased ATGL512 Cell Reports 5, 508–520, October 31, 2013 ª2013 The Authorsexpression, while reducing HSL expression in the liver (Fig-
ure 4B). More consistently, we observed coordinate downregu-
lation of genes involved in de novo fatty acid synthesis and
lipogenesis (SREBP1c, FAS, ACC-1, and SCD-1) in ABHD6
ASO-treated mouse liver (Figures 4B and 4C). In agreement,
the in vivo rate of de novo fatty acid synthesis was reduced by
62% in ABHD6 ASO-treated mice (Figure 4D). Consistent with
this, primary hepatocytes isolated from ABHD6 ASO-treated
livers showed decreased rates of 3H-oleate esterification into
Figure 4. ABHD6 Is a Critical Regulator of De Novo Lipogenesis
(A) Biologic processes overrepresented among upregulated and down-
regulated genes identified by microarray analysis from livers of ABHD6 ASO-
treated mice compared with control ASO-treated mice fed a high-fat diet.
(B) qPCR confirmation of hepatic genes identified by microarray analyses in
HFD-fedmice; data represent themean ±SEM (n = 4); *p < 0.05 (versus control
ASO group). ATGL, adipose triglyceride lipase; HSL, hormone-sensitive lipase,
MAGL, monoacylglycerol lipase; SREBP1c, sterol response element-binding
protein 1c; FAS, fatty acid synthase; ACC1, acetyl-CoA carboxylase 1; SCD1,
Ctriacylglycerol (Figure 4E) as well as decreased de novo lipogen-
esis rates as measured by the kinetic conversion of 14C-acetate
into 14C-triacylglycerol (Figure 4F). It is important to note that all
four ASOs targeting the knockdown of ABHD6 at different sites
consistently decreased hepatic lipogenic gene expression (Fig-
ures S1B, S1C, and S1D), without altering adipose tissue (Fig-
ure 2J) or hypothalamic (Figure S1E) lipogenic gene expression.
We also examined the phosphorylation state of both AMPKa and
AMPKb in mouse liver, but noted no obvious differences in acti-
vation state (Figure S2E).
ABHD6 Is a Minor Monoacylglycerol Lipase in Mouse
Liver, and Knockdown Does Not Alter Hepatic
Endocannabinoid Levels or Acute Cannabinoid
Receptor 1 Signaling
Given that ABHD6 was previously described as a monoacylgly-
cerol lipase in the brain (Blankman et al., 2007; Marrs et al.,
2010, 2011), we carefully examined whether ABHD6 knock-
down resulted in accumulation of hepatic MAG species, or
whether ABHD6 knockdown resulted in hyperactivation of the
ECB system in mouse liver. ABHD6 knockdown did not alter
the total hepatic levels of MAG in mice fed either chow or a
high-fat diet (Figure 3B), although two species of MAG contain-
ing oleate (18:1) or linoleate (18:2) did modestly increase
(Figure 5A). In contrast, hepatic levels of endocannabinoid
lipids (2-AG and anandamide) were not changed by ABHD6
ASO treatment (Figures 5B and 5C). There was also no
apparent difference in total hepatic MAG lipase activity with
ABHD6 knockdown (data not shown). Given that previous
studies have demonstrated that the CB1-dependent signaling
is largely desensitized when 2-AG builds up as a result of
monoacylglycerol lipase (MAGL) inhibition or genetic deficiency
(Schlosburg et al., 2010; Taschler et al., 2011), we carefully
examined acute CB1 signaling in ABHD6 ASO-treated mice.
To examine the effect of ABHD6 knockdown on CB1 receptorstearoyl-CoA desaturase 1; SREBP2, sterol response element-binding protein
2; HMG-Red, 3-hydroxy-3-methylglutaryl-CoA reductase; LDLr, low-density
lipoprotein receptor; PPARa, peroxisome proliferator-activated receptor
alpha; CPT-1a, carnitine palmitoyltransferase 1; AOX, acyl-CoA oxidase; AU,
arbitrary unit.
(C) Hepatic lipogenic protein expression in mice treated with a control non-
targeting ASO or two independent ABHD6 ASOs for 12 weeks.
(D) In vivo synthesis rates of fatty acids in livers of control and ABHD6 ASO-
treated mice. HFD-fed male mice (6 weeks of diet and ASO) were injected
intraperitoneally with 3H-labeled water, and 1 hr later livers were removed for
measurement of 3H-labeled fatty acids as described in Experimental Pro-
cedures.
(E) Esterification rates in primary hepatocytes isolated from ASO-treated mice.
Hepatocytes were kinetically labeled with 3H-oleate to follow the conversion
into 3H-triacylglycerol in the presence of lipase inhibitors to block lipolysis/
re-esterification. Data represent the mean ± SEM (n = 3) from a representative
experiment, which was repeated twice in pooled hepatocytes isolated from
ASO-treated mice; *p < 0.05 (versus control ASO group).
(F) De novo lipogenesis rates in primary hepatocyte isolated from ASO-treated
mice. Hepatocytes were kinetically labeled with 14C-acetate to follow the
conversion into 14C-triacylglycerol in the presence of lipase inhibitors to block
lipolysis/re-esterification. Data represent the mean ± SEM (n = 3) from a
representative experiment, which was repeated twice in pooled hepatocytes
isolated from ASO-treated mice; *p < 0.05 (versus control ASO group).
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Figure 5. ABHD6 Knockdown Results in
Modest Alterations in Hepatic Monoacylgly-
cerol Levels yet Does Not Alter Hepatic
Endocannabinoid Levels or Acute Cannabi-
noid Receptor 1 Signaling in Mouse Liver
(A) Male C57BL/6mice were fed a chow or high-fat
diet (HFD) and treated with a control ASO or an
ASO targeting ABHD6 for 12 weeks. The hepatic
levels of monoacylglycerol (MAG) species were
measured by mass spectrometry as described in
Experimental Procedures. Data represent the
mean ± SEM (n = 6); *p < 0.05 (versus control ASO
within each diet).
(B and C) Male C57BL/6 mice were fed a high-fat
diet (HFD) and treated with a control nontargeting
ASO or an ASO targeting the knockdown of
ABHD6 for 12 weeks. The hepatic levels of 2-
arachidonylglycerol (B) and anandamide (C) were
measured by mass spectrometry as described in
Experimental Procedures. Data represent the
mean ± SEM (n = 6), and no significant differences
were found.
(D) Male C57BL/6 mice were fed a high-fat diet
(HFD) and treated with a control ASO or an ASO
targeting ABHD6 for 8 weeks. Following 8 weeks
of ASO treatment, mice were fasted for 12 hr and
subsequently injected with either vehicle or CP-
55,940 (0.1 mg/kg) directly into the portal vein.
Exactly 5 min later, livers were excised and
immediately snap frozen in liquid nitrogen. Protein
extracts from the liver were analyzed by western
blotting for ABHD6, phospho-ERK (Thr202/
Tyr204), total ERKMAPK, monoacylglycerol lipase
(MAGL), or beta actin (b-actin); three representa-
tive animals are shown for each group.desensitization, we administered the cannabinoid receptor
(CB1) agonist CP-55,940 or vehicle directly into the portal
vein of ASO-treated mice and followed downstream signaling.
ABHD6 knockdown did not alter CP-55,940-induced ERK-
MAPK activation compared to control ASO-treated mice (Fig-
ure 5D). However, basal activation of ERK-MAPK was lower
in ABHD6 ASO-treated mice (Figure 5D), indicating that
ABHD6 may be involved in regulating other inputs into ERK-
MAPK activation.
ASO-Mediated Inhibition of ABHD6 Uncovers a Role for
ABHD6 in Lysophospholipid Metabolism
Interestingly, a number of phospholipids and lysophospholipids
accumulated to varying degrees in ABHD6 ASO-treated
livers (Figure 6), implicating themaspotential physiologically rele-514 Cell Reports 5, 508–520, October 31, 2013 ª2013 The Authorsvant substrates. ABHD6 knockdown
significantly increased total hepatic levels
of phosphatidylcholine (PC), lysophos-
phatidylcholine (LPC), phosphatidyletha-
nolamine (PE), lysophosphatidylethanola-
mine (LPE), phosphatidylglycerol (PG),
lysophosphatidylglycerol (LPG), phos-
phatidylinositol (PI), lysophosphatidylino-
sitol (LPI), and phosphatidylserine (PS)(Figures 6B, 6C–6F, 6H–6L, S5, and S6) without altering hepatic
levels of phosphatidic acid or lysophosphatidic acid species (Fig-
ures 6A, 6G,S7C, andS6F).Of interest, themostprominent accu-
mulation was observed for nearly all species of LPG (Figures 6J
and S6A) and PG (Figures 6D and S5C) in ABHD6 knockdown
mice. Inhibition of ABHD6 also promoted the accumulation of
several ether-linked glycerophospholipids (plasmalogens)
including all detected molecular species of plasmanylcholines
(Figure S7A) and plasmenylethanolamines (Figure S7B). In paral-
lel, nearly all species of LPE, LPG, LPI, and lysophosphatylserine
(LPS) were increased with ABHD6 knockdown regardless of diet
(Figure S6). We subsequently tested whether ABHD6 can hydro-
lyze phospholipid and neutral lipid substrates in vitro. To accom-
plish this, we expressed a GST-tagged ABHD6 in S. cerevisiae
(Figure 6M), and the purified protein was incubated in the
presence of a panel of lipid substrates (Figures 6M–6Q). As previ-
ously demonstrated with ABHD6-expressing cell homogenates
(Blankman et al., 2007; Marrs et al., 2010, 2011; Navia-Paldanius
et al., 2012), ABHD6 hydrolyzes MAG substrates including 1,(3)-
rac- oleoylglycerol and 2-oleoylglycerol, and its ability to hydro-
lyzeMAG substrates is lost when the active site serine ismutated
to alanine (S148A) (Figure 6N). However, in saturation kinetic
experiments recombinant MAGL exhibited a 11-fold higher spe-
cific activity (Vmax = 5359.3 mmol/hr*mg) than ABHD6 (Vmax =
478.6 mmol/hr*mg) (Figure 6O), and under the applied conditions
the apparent KM was lower for MAGL (KM = 1.2) compared to
ABHD6 (KM = 1.9), indicating that ABHD6 has a lower affinity for
MAG.
Next, we investigated whether affinity-purified ABHD6 hydro-
lyzes the other glycerophospholipid substrates identified by
in vivo lipidomics (Figures 6A–6L). Recombinant ABHD6 showed
considerable lipase activity toward several lysophospholipids
including LPG, LPA, and LPE but not LPC (Figure 6P). In
contrast, ABHD6 exhibited no lipase activity against major phos-
pholipid classes including PG, PE, PA, PS, and PC (Figure 6P).
The highest activity was observed using LPG as a substrate
(Figures 6P and 6Q), and this activity was even higher in a deter-
gent-containing (5 mMCHAPS) buffer system. Under these con-
ditions, we determined a Vmax of 93.2 mmol/hr*mg and a KM of
0.75 (Figure 6Q). Furthermore, purified ABHD6 exhibited low
activity against retinyl palmitate (RP) and rac-dioleoylglycerol,
whereas no activity was observed in the presence of trioleoylgly-
cerol or cholesteryl oleate (data not shown). Notably, ABHD6’s
activity against 1,3-diacylglycerol was 5-fold higher in compari-
son to 1,2(2,3)-diacylglycerol (data not shown). The ability of
ABHD6 to hydrolyze neutral lipid and lysophospholipid sub-
strates was completely lost when the active site serine was
mutated to alanine (Figure 6; data not shown). It is important to
note that MAGL did not hydrolyze any of the tested phospholipid
substrates (data not shown) annotating MAGL, but not ABHD6,
as a specific MAG hydrolase. Taken together, these observa-
tions suggest that ABHD6 can act both as a monoacylglycerol
lipase and lysophospholipase exhibiting a preference for LPG
among the tested lysophospholipids.
Small Molecule Inhibition of ABHD6 Protects against
High-Fat-Diet-Induced Glucose Intolerance and Obesity
ASO-mediated inhibition is a tissue-restricted therapeutic
approach, targeting knockdown in metabolic tissues (liver, white
adipose tissue, and kidney) without altering ABHD6 expression
or activity in many other tissues (brain, spleen, brown adipose
tissue). However, ABHD6 is ubiquitously expressed (Figure 1B),
begging the question whether systemic inhibition would likewise
protect against metabolic disease. Therefore, we determined
whether a small molecule inhibitor of ABHD6, which would be
predicted to target all tissues including the brain, also provides
protection against the metabolic disorders driven by high-fat-
diet feeding. Treatment with the small molecule inhibitor of
ABHD6 (WWL-70) protected mice from high-fat-diet-induced
body weight gain (Figure 7A), which was largely due to a reduc-
tion in adipose tissue mass (Figure 7B). WWL-70 treatment also
protected mice against high-fat-diet-induced glucose intoler-
ance. Although there was a trend toward a decrease, WWL-70Cdid not significantly reduce hepatic triacylglycerol levels in
high-fat-diet-fed mice (Figure 7D), which contrasts with what is
observed with ASO-mediated inhibition (Figure 3). These results
show that inhibition of ABHD6 using a systemic inhibitor
improves some aspects of the metabolic syndrome but does
not protect against hepatic steatosis to the same degree that
ASO-mediated inhibition does (Figure 3).
DISCUSSION
Although other members of the ABHD protein family have been
clearly linked to lipid signaling and metabolic disease (Lefe`vre
et al., 2001; Fiskerstrand et al., 2010; Long et al., 2011; Simon
and Cravatt 2006; Montero-Moran et al., 2010; Blankman et al.,
2007; Lord et al., 2012; Brown et al., 2010), this study documents
a role for ABHD6 in promoting the metabolic disorders driven by
high-fat-diet feeding. The major findings of this work demon-
strate the following: (1) peripheral knockdown of ABHD6 protects
mice from high-fat-diet-induced obesity, (2) ABHD6 knockdown
protects mice from high-fat-diet-induced hepatic steatosis and
associated insulin resistance, (3) ABHD6 is a critical regulator
of hepatic de novo lipogenesis, and (4) ABHD6 hydrolyzes
several lipid substrates in vitro, including lysophospholipids
with preference for LPG. Accordingly, we show that inhibition of
ABHD6 results in the accumulation of LPG and PG in vivo. Taken
together, our results reveal that ABHD6 plays a role in the devel-
opment of the metabolic syndrome.
ABHD6hasbeenshown to regulate theECBsystem in thebrain
due to its ability to hydrolyze specific pools of 2-AG (Blankman
et al., 2007; Marrs et al., 2010, 2011). We also confirmed that
ABHD6 exhibits MAG lipase activity in vitro (Figures 6N and 6O).
Our data suggest, however, that ABHD6 is a minor contributor
to MAG lipolysis and ECB signaling in mouse liver. This finding
is supported by the fact that total MAG levels do not change (Fig-
ure 3B), 2-AGandanandamide levels are not elevated (Figures 5B
and 5C), and acute CB1-driven activation of ERK-MAPK is unal-
tered with ABHD6 knockdown (Figure 5D), arguing against CB1
receptor desensitization. It is important to contrast these findings
with the very striking accumulation of hepatic 2-AG, marked
reduction in hepatic MAG lipase activity, and CB1 receptor
desensitization seen in both MAGL/ mice and mice treated
chronically with a specific MAGL inhibitor (Taschler et al., 2011;
Schlosburg et al., 2010). It is also important to note that if
ABHD6 was a major regulator of hepatic 2-AG levels, one would
anticipate that ABHD6 knockdown would cause hyperactivation
of hepatic CB1 signaling, which has been reported to promote
hepatic steatosis through increasing de novo lipogenesis (Osei-
Hyiaman et al., 2005, 2008). However, we observed that ABHD6
knockdown protected mice from high-fat-diet-induced hepatic
steatosis and suppressed de novo lipogenesis (Figure 4). Collec-
tively, these results support the notion that MAGL is the predom-
inant MAG lipase in mouse liver. We did, however, see minor
elevations in 18:1 and 18:2 MAG (Figure 5A), making it possible
that ABHD6’s ability to hydrolyze these lipids may affect other
signaling processes regulating hepatic de novo lipogenesis.
ABHD6 contributes to 2-AG hydrolysis and ECB signaling in
the brain (Blankman et al., 2007; Marrs et al., 2010; Marrs
et al., 2011). However, MAGL accounts for the vast majorityell Reports 5, 508–520, October 31, 2013 ª2013 The Authors 515
Figure 6. ASO-Mediated Knockdown Annotates ABHD6 as a Physiological Lysophospholipase in Mouse Liver
Mice were fed a chow or high-fat diet and treated with a control nontargeting ASO or an ASO targeting ABHD6 for 12 weeks (A–L).
(A) Total hepatic phosphatidic acid (PA) levels.
(B) Total hepatic phosphatidylcholine (PC) levels.
(C) Total hepatic phosphatidylethanolamine (PE) levels.
(D) Total hepatic phosphatidylglycerol (PG) levels.
(E) Total hepatic phosphatidylinositol (PI) levels.
(F) Total hepatic phosphatidylserine (PS) levels.
(G) Hepatic levels of 16:0 lysophosphatidic acid (LPA).
(H) Hepatic levels of 18:2 lysophosphatidylcholine (LPC).
(I) Hepatic levels of 18:2 lysophosphatidylethanolamine (LPE).
(J) Hepatic levels of 18:2 lysophosphatidylglycerol (LPG).
(K) Hepatic levels of 18:0 lysophosphatidylinositol (LPI).
(L) Hepatic levels of 18:0 lysophosphatylserine (LPS). All data in (A)–(L) represent the mean ± SEM (n = 6); *p < 0.05 (versus control ASO within each diet). In
(M)–(Q), recombinant ABHD6 or monoacylglycerol lipase (MAGL) were used to test in vitro substrate specificity of both enzymes.
(legend continued on next page)
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(>80%) of 2-AG hydrolysis in the brain, whereas ABHD6 only
accounts for less than 5% of the total 2-AG hydrolase activity
(Blankman et al., 2007). Our studies suggest that ABHD6’s addi-
tional ability to hydrolyze a variety of lipid substrates may be
important in linking lipid mediator signaling to the metabolic ad-
aptations resulting from high-fat-diet feeding. In this study, we
utilized a targeted lipidomics approach to identify substrates of
ABHD6 in mouse liver and verified LPG as a bona fide substrate
in vitro and in vivo. LPG is considered a bioactive lipid, although
its receptor remains to be identified (Makide et al., 2009; Jo et al.,
2008). Lysophospholipids have previously been implicated in
promoting metabolic disease via their ability to dictate mem-
brane dynamics and initiate cell signaling, particularly in immune
cells (Wymann and Schneiter, 2008; Skoura and Hla, 2009). We
assume that defective LPG degradation favors the re-esterifica-
tion of LPG to PG, which may explain the elevated PG levels in
the ABHD6-knockdown liver. PG is also an important precursor
for other complex lipids including cardiolipin and bis(monoacyl-
glycerol)phosphate (Hullin-Matsuda et al., 2007). Therefore,
changes in ABHD6-driven LPG metabolism could alter many
mitochondrial or lysosomal metabolic processes. Interestingly,
a recent genome-wide association study (GWAS) in Pima Indians
identified the lysophosphatidylglycerol acyltransferase 1
(LPGAT1) loci as being predictive of body mass index (BMI),
providing additional genetic evidence that LPG metabolism
may influence BMI and adiposity (Traurig et al., 2013).
Projecting forward, there are several important factors to
consider for developing ABHD6 as a drug target. For example,
it will be important to determine how ABHD6 expression and
subcellular distribution are regulated in diverse cell and tissue
contexts. Furthermore, it will be essential to evaluate whether
ABHD6 has other physiological substrates in vivo, and if tis-
sue-selective inhibitors will be necessary for safe and effective
prevention of metabolic disease. Another important consider-
ation will be whether chronic ABHD6 inhibition results in CB1
receptor desensitization in the brain or other receptor signaling
abnormalities. Our data suggest that chronic ABHD6 inhibition
with ASOs does not cause CB1 receptor desensitization in
mouse liver (Figure 5D). However, whether CB1 receptor desen-
sitization occurred in other tissues was not examined here. As
previously documented (Bachovchin et al., 2010), we show
that ABHD6 is ubiquitously expressed in mice (Figure 1B). Addi-
tional studies will be required to assess the risk versus benefits of
inhibiting ABHD6 in specific tissues. Our studies provide key
information in regards to ABHD6’s biochemical and physiolog-
ical role in certain peripheral tissues (liver, adipose, and kidney)
given the tissue-selective inhibition observed with ASOs (Fig-(M) Coomassie stain of purified GST-tagged murine ABHD6, which was express
weight ladder; lane 2, affinity purified ABHD6.
(N) Degradation of 1(3)-oleoylglycerol [1,(3)-rac-OG; 3 mM] and 2-oleoylglycerol
lacking the putative active serine (S148G).
(O) Saturation kinetics of ABHD6 and monoacylglycerol lipase (MAGL) using
representative of at least two independent experiments.
(P) PurifiedGST-ABHD6was incubated in the presence of a panel of potential glyc
are presented as the mean ± SD and are representative of at least two independ
(Q) Saturation kinetics of ABHD6 using 1-oleoyl lysophosphatidylglycerol (LPG) as
two independent experiments.
See also Figures S4, S5, and S6.
Cure S1). However, our studies do not address ABHD6’s primary
role in other tissues where it is abundantly expressed (brain,
small intestine, pancreas, and skeletal muscle), all of which are
key sites regulatory sites for energy metabolism.
It is important to compare and contrast the results of inhibiting
ABHD6 with systemic small molecule inhibitors versus a more
selective approach using ASO technology. Although both
ASO-mediated and WWL-70-mediated inhibition of ABHD6 pro-
tected against high-fat-diet-induced obesity and glucose intoler-
ance, only ABHD6 ASO treatment improved hepatic steatosis.
Themechanism underlying this difference is unclear at this point,
but this most likely stems from systemic versus tissue-restricted
inhibition. Interestingly, ASO-mediated inhibition of ABHD6 was
not associated with alteration in food intake at any time point
examined (Figure 2H). However, WWL-70 treatment caused a
20% reduction in food intake (data not shown), indicating that
the mechanism by which WWL-70 protected against obesity
and glucose intolerance is likely driven by hypophagia, whereas
ASO-mediated inhibition more specifically dampened hepatic
lipogenesis and increases in energy expenditure.
In addition to further studies with selective ABHD6 inhibitors,
the generation of global and conditional knockoutmousemodels
is necessary to define the tissue-specific role for ABHD6 in
chronic diseases of altered lipid metabolism. In summary, our
data identify ABHD6 as a key determinant in the pathogenesis
of high-fat-diet-induced obesity, insulin resistance, and hepatic
steatosis. Furthermore, we have uncovered lipid substrates of
ABHD6 by coupling in vivo lipidomic and in vitro biochemical
approaches. Looking forward, we believe that utilizing a similar
in vivo loss-of-function approach may prove useful for mapping
natural enzyme-substrate relationships for the other uncharac-
terized enzymes in the ABHD family. It is interesting to note
that during the preparation of this manuscript that another
ABHD enzyme ABHD12 was likewise identified as a dual mono-
acylglycerol lipase and lysophospholipase with preference
toward lysophosphatidylserine species using a similar in vivo
substrate identification approach (Blankman et al., 2013). Taken
together, our findings suggest that ABHD6 is a key lipase
involved in monoacylglycerol and lysophospholipid hydrolysis,
and that ABHD6 inhibitors hold promise as therapeutics for
obesity, nonalcoholic fatty liver disease, and type II diabetes.EXPERIMENTAL PROCEDURES
Mice
For ABHD6 knockdown studies, at 6–8 weeks of age, male C57BL/6N mice
(Harlan) were either maintained on standard rodent chow or switched to aed in S. cerevisiae and purified by affinity chromatography; lane 1, molecular
[2-OG; 3 mM] by wild-type (WT) GST-ABHD6 and a mutant variant of ABHD6
1(3)-monoolein as substrate. Data are presented as the mean ± SD and
erophospholipid substrates and the release of fatty acids was determined. Data
ent experiments. *p < 0.05 (lysophospholipid versus phospholipid)
substrate. Data are presented as the mean ± SD and representative of at least
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Figure 7. Small Molecule Inhibition of ABHD6 Protects against High-
Fat-Diet-Induced Glucose Intolerance and Obesity
Male C57BL/6 mice were fed a high-fat diet (HFD) and treated with a vehicle or
10 mg/kg of the ABHD6 inhibitor WWL-70 for 8 weeks.
(A) Body weight.
(B) Epididymal white adipose tissue (WAT) weight.
(C) Glucose tolerance tests in mice treated with inhibitor and diet for 6 weeks.
(D) Total hepatic triacylglycerol levels in mice treated with inhibitor and diet for
8 weeks.
Data represent the mean ± SEM (n = 10); *p < 0.05 (versus vehicle).high-fat diet for a period of 4–12 weeks and were simultaneously injected with
murine-specific ABHD6 antisense oligonucleotides biweekly (25 mg/kg body
weight [BW]) as previously described (Lord et al., 2012; Brown et al., 2008a,518 Cell Reports 5, 508–520, October 31, 2013 ª2013 The Authors2008b, 2010). For small molecule inhibitor studies, mice were fed a high-fat
diet and simultaneously treated with either a vehicle or 10 mg/kg WWL-70 for
8 weeks. Intraperitoneal glucose tolerance tests and insulin tolerance tests
were performed essentially as previously described (Brown et al., 2008a,
2010) in mice treated with diet and ASO for 10–11 weeks. Metabolic measure-
ments were conducted in the comprehensive lab animal monitoring systems
(CLAMS) from Columbus Instruments. Body composition was determined by
MRI. All mice were maintained in an American Association for Accreditation of
Laboratory Animal Care (AALAC)-approved specific pathogen-free environ-
ment on a 12:12 hr light:dark cycle and allowed free access to food and water.
All experimentswere performedwith theapproval of the institutional animal care
andusecommittee atWakeForestSchool ofMedicine. Adetaileddescriptionof
all mouse experiments is provided in the Extended Experimental Procedures.
In Vivo Cannabinoid Receptor Signaling Analyses
Mice were injected with control ASO or ABHD6 ASOb and maintained on a
high-fat diet for a period of 8 weeks prior to experiment. After an overnight
fast (9:00 p.m. to 9:00 a.m.), mice were anesthetized with isoflurane (4% for
induction, 2% for maintenance) and were maintained on a 37C heating pad
to control body temperature. A minimal midline laparotomy was performed,
and the portal vein was visualized. Thereafter, mice received either vehicle
(cremophor EL:ethanol:saline at a 1:1:18 ratio) or the CB1 agonist (CP-
55,490, Cayman Chemical #13241) at a dose of 0.1 mg/kg BW directly into
the portal vein. Exactly 5 min later, the liver was excised and immediately
snap frozen in liquid nitrogen. Protein extracts from tissues were analyzed
by western blotting to examine CB1 signaling as described below.
In Vivo Determination of Very-Low-Density Lipoprotein Secretion,
Intestinal Fat Absorption, and De Novo Fatty Acid Synthesis Rates
VLDL secretion rates were determined using the detergent block method (Li
et al., 1996). Dietary fat absorption was measured using the Olestra method
(Jandacek et al., 2004), and de novo fatty acid synthesis was measured using
the 3H-water method (Shimano et al., 1996). These methods are described in
detail in the Extended Experimental Procedures.
Primary Hepatocyte Studies
Hepatocyteswere isolated fromchow-fedASO-treatedmice using the collage-
nase perfusion method, and the rate of de novo lipogenesis was determined
following the conversion of 14C-acetate and 3H-oleate into newly synthesized
triacylglycerol in thepresenceof lipase inhibitors toblock lipolysis/re-esterifica-
tion. A detailed method is provided in the Extended Experimental Procedures.
Generation and Purification of a Polyclonal Antibody against ABHD6
A maltose binding protein ABHD6 fusion protein construct was generated to
create affinity-purified rabbit polyclonal antibodies against murine ABHD6. A
detailed description of cloning, expression, and purification are included in
the Extended Experimental Procedures.
Immunoblotting
Whole tissue homogenates were made from multiple tissues in a modified
RIPA buffer, and western blotting was conducted as previously described
(Brown et al., 2004).
Microarray and Quantitative Real-Time PCR Analysis of Gene
Expression
Tissue RNA extraction was performed as previously described for all mRNA
analyses (Lord et al., 2012; Brown et al., 2008a, 2008b, 2010). Microarray
analyses were performed by the Wake Forest School of Medicine Microarray
Shared Resource Core using standard operating procedures, and quantitative
real-time PCR (qPCR) analyses were conducted as previously described (Lord
et al., 2012; Brown et al., 2008a, 2008b, 2010). A detailed description of RNA
methods is available in the Extended Experimental Procedures.
Hepatic Lipid Analyses
Extraction of liver lipids and quantification of molecular species by mass spec-
trometry was performed as previously described (Lord et al., 2012; Ivanova
et al., 2007; Myers et al., 2011; Callender et al., 2007).
Purification of GST-Tagged Murine ABHD6 for Enzymology Studies
The coding sequence of murine ABHD6 was cloned into the yeast expression
vector pYEX4T-1. The resulting protein was purified using glutathione-Sephar-
ose beads and used for enzymology studies as described in the Extended
Experimental Procedures.
Statistical Analysis
All data are expressed as the mean ± SEM or SD and were analyzed using
either a one-way or two-way analysis of variance (ANOVA) followed by Stu-
dent’s t tests for post hoc analysis using JMP version 5.0.12 software (SAS
Institute).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and one tables and can be foundwith this article online at http://dx.doi.
org/10.1016/j.celrep.2013.08.047.
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